Market closedNon-fractional
Erasca/ERAS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Ticker
ERAS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
126
Website
www.erasca.com
Erasca Metrics
BasicAdvanced
$891M
Market cap
-
P/E ratio
-$0.84
EPS
1.06
Beta
-
Dividend rate
Price and volume
Market cap
$891M
Beta
1.06
Financial strength
Current ratio
10.139
Quick ratio
9.872
Long term debt to equity
17.618
Total debt to equity
19.048
Management effectiveness
Return on assets (TTM)
-21.39%
Return on equity (TTM)
-37.60%
Valuation
Price to book
1.71
Price to tangible book (TTM)
1.71
Price to free cash flow (TTM)
-4.53
Growth
Earnings per share change (TTM)
-54.45%
3-year earnings per share growth (CAGR)
-42.71%
What the Analysts think about Erasca
Analyst Ratings
Majority rating from 9 analysts.
Erasca Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$35M
17.85%
Profit margin
0.00%
NaN%
Erasca Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.21
-$0.20
-$0.20
-$0.23
-
Expected
-$0.24
-$0.22
-$0.23
-$0.20
-$0.18
Surprise
-11.02%
-9.09%
-11.95%
14.43%
-
Erasca News
AllArticlesVideos
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
GlobeNewsWire·2 months ago
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
GlobeNewsWire·2 months ago
Erasca Announces Pricing of Underwritten Offering of Common Stock
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Erasca stock?
Erasca (ERAS) has a market cap of $891M as of July 27, 2024.
What is the P/E ratio for Erasca stock?
The price to earnings (P/E) ratio for Erasca (ERAS) stock is 0 as of July 27, 2024.
Does Erasca stock pay dividends?
No, Erasca (ERAS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Erasca dividend payment date?
Erasca (ERAS) stock does not pay dividends to its shareholders.
What is the beta indicator for Erasca?
Erasca (ERAS) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Erasca stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.